Medsenic   Report issue

For profit Phase 2
Founded: Paris France (2010)
Status: No NME R&D (2010)

Organization Overview

First Clinical Trial
2013
NCT01738360
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Medsenic Company

Active Ingredients

Drugs in Phase 2 Trials (1)

arsenic trioxide (trisenox) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Graft vs Host Disease (Phase 2)

Immune System Diseases (Phase 2)

Lupus Erythematosus, Systemic (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1